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Previous studies have shown that porcine aortic
smooth muscle cells (SMCs) secrete two insulin-like
growth factor-binding proteins (IGFBP), IGFBP-2 and
-4, and that these IGFBPs modulate IGF-I-stimulated
SMC proliferation and migration. In this study we dem-
onstrate that porcine SMCs express IGFBP-5 mRNA and
synthesize and secrete the protein. In this cell type, the
biosynthesis of IGFBP-5 is up-regulated by IGF-I. This
increase in IGFBP-5 synthesis is accompanied by an
increase in the steady-state mRNA levels. The induction
of IGFBP-5 mRNA by IGF-I is time- and dose-dependent
and requires de novo protein synthesis. IGF-II and insu-
lin also increase IGFBP-5 mRNA levels at high doses. An
IGF-I analog with normal affinity for the IGF-I receptor
but reduced affinity for IGFBPs evokes a similar in-
crease. Another analog that binds to IGFBPs but not to
the receptor has no effect, indicating that this effect of
IGF-I is mediated through the IGF-I receptor. The IGF-
I-induced IGFBP-5 gene expression is cell type-specific
because IGF-I had no such effect in other cell types
examined. Nuclear run-on assays revealed that IGF-I
increased transcription rate of the IGFBP-5 gene, while
IGF-I did not change the IGFBP-5 mRNA stability. Fur-
thermore, the IGFBP-5 promoter was 3.5-fold more ac-
tive in directing expression of the luciferase reporter
gene in IGF-I-treated aortic SMCs as compared to con-
trol cells, whereas the luciferase activity remained the
same in control- and IGF-I-treated fibroblasts. These
results suggest that IGF-I up-regulates IGFBP-5 synthe-
sis by transcriptionally activating the IGFBP-5 gene in
aortic SMCs.
Many studies have linked the accumulation of aortic smooth
muscle cells (SMCs)1 to the development of atherosclerotic
lesions. This accumulation is due to a combination of SMC
proliferation, directed migration from the arterial media into
the intima (1, 2), and inhibition of apoptosis (3). All of these
events are modulated by a number of peptide growth factors
including insulin-like growth factors (IGFs). SMCs in culture
have been shown to synthesize IGF-I, and this endogenously
produced IGF-I stimulates SMC proliferation in an autocrine
fashion (4–6). In vivo, IGF-I mRNA and immunoreactive IGF-I
are detected in intimal lesions that develop after angioplasty
(7). IGF-I mRNA and immunoreactive IGF-I levels both in-
crease severalfold after balloon denudation injury, and these
increases temporally precede an associated increase in SMC
proliferation (8, 9). Likewise, SMCs possess IGF-I receptors
and selective inhibition of the receptors by antisense targeting
results in marked reduction in SMC proliferation (9, 10). These
observations together with the well established fact that IGF-I
is a mitogen for SMCs suggest that the local production of
IGF-I plays an important role in SMC proliferation (11). In
addition to its role in mitogenesis, IGF-I has recently been
shown to stimulate SMC migration. Bornfeldt et al. (12)
showed that IGF-I stimulates SMC directed migration using a
Boyden chamber assay. Studies from our laboratory have
shown that IGF-I and IGF-II stimulate SMC migration in a
monolayer wounding assay, and this response is mediated by
the IGF-I receptor (13). Thus, IGF-I is important for SMC
proliferation and migration and may therefore play an impor-
tant role in the development of atherosclerotic lesions.
The bioactivities of IGFs are modulated by a group of high
affinity specific binding proteins (IGFBPs). Six distinct IG-
FBPs, designated as IGFBP-1 to IGFBP-6, have been identified
in mammalian systems to date (14, 15). These proteins share
relatively high amino acid sequence similarity, but each has
distinct structural and biochemical properties that partially
determine whether they act to inhibit or potentiate IGF bioac-
tivity. Previous studies from our laboratory have shown that
porcine aortic SMCs secrete IGFBP-2 and -4, and that they
both modulate IGF-I-stimulated DNA synthesis and cell migra-
tion in this cell type (13, 16–18). The availability of IGFBP-2
and -4 in SMCs is regulated by IGFs, PDGF, insulin, and other
factors (17, 18). While PDGF or insulin treatment results in
moderate increases in IGFBP-2 and -4 synthesis, IGFs accel-
erate the degradation of the inhibitory IGFBP-4 by activating
specific proteases. These findings indicate that the presence of
IGFBPs in the area of the vascular lesion may play a role in
modifying IGF activity, potentially resulting in modulation of
SMC proliferation and migration.
In the present study, we report that porcine aortic SMCs
express IGFBP-5 mRNA and synthesize and secrete IGFBP-5.
Our data indicate that the synthesis of IGFBP-5 is up-regu-
lated by its own ligand, IGF-I. Of particular interest to us was
that IGF-I increased the transcription rate of the IGFBP-5
gene without significantly affecting the mRNA stability and
that this response is specific for aortic SMCs.
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EXPERIMENTAL PROCEDURES
Materials—Fetal bovine serum (FBS), Dulbecco’s minimum essential
medium, Eagle’s minimum essential medium, and penicillin-strepto-
mycin were purchased from Life Technologies, Inc. Trypsin was ob-
tained from Boehringer Mannheim. Recombinant human IGF-I and rat
IGF-II were purchased from Bachem, Inc. (Torrance, CA). Recombinant
human FGF and PDGF-BB were purchased from Intergen (Purchase,
NY). Two antisera against human IGFBP-5 were prepared as described
previously (19). They have no cross-reactivity for IGFBP-2 and -4.
Enzymes were purchased from the following commercial suppliers:
Promega Corp. (Madison, WI), Boehringer Mannheim, New England
Biolabs (Beverly, MA), U. S. Biochemical Corp. Deoxyribonucleotides
and radionucleotides were purchased from Boehringer Mannheim, Am-
ersham Corp., and DuPont NEN. TA cloning kit was purchased from
Invitrogen (San Diego, CA), and plasmid pGL2-Basic from Promega.
Materials for DNA purification were purchased from Qiagen (Chats-
worth, CA). Oligonucleotides were synthesized by the Nucleic Acids
Core Faculty, University of North Carolina, Chapel Hill.
Cell Culture—Porcine aortic SMCs were isolated from thoracic aortas
of 3-week-old piglets. The cells were grown in 10-cm dishes (Falcon
Laboratory Division) in Dulbecco’s minimum essential medium supple-
mented with 4.5 g/liter glucose, 4 mM glutamine, penicillin (100 units/
ml), and streptomycin (100 mg/ml) plus 10% FBS. Human intestinal
smooth muscle cells (HISM, American Type Culture Collection, Rock-
ville, MD) were grown in the same medium. Human newborn aortic
SMC were a gift from Dr. Stephen Schwartz, University of Washington.
These cells were grown in Waymouth’s medium supplemented with
penicillin (100 units/ml) and streptomycin (100 mg/ml) plus 10% FBS.
Human fetal dermal fibroblasts (GM10, Human Mutant Genetic Cell
Repository, Camden, NJ) and human glioblastoma tumor cells (T98G,
American Type Culture Collection, Rockville, MD) were maintained in
Eagle’s minimum essential medium supplemented with serine (21 mg/
ml), pyruvate (110 mg/ml), asparagine (30 mg/ml), penicillin (100 units/
ml), streptomycin (100 mg/ml), and 10% FBS. The medium was changed
every 4th day until cells became confluent.
Western Ligand Blot and Immunoblot Analysis—In order to identify
the IGFBP-5 secreted by SMC, samples containing 0.5 ml of culture
medium were concentrated 20 times by ultrafiltration through a Cen-
tricon-10 microconcentrator (Amicon, Berkeley, MA). The proteins were
separated by SDS-PAGE using 12.5% polyacrylamide gels under non-
reducing conditions as described previously (17). After transfer to filters
(Immunobilon P, 0.45-mm pore size, Millipore, Bedford, MA), the filters
were probed with 125I-IGF-I and autoradiographs were obtained by
exposure to x-ray films (Kodak AR film, Eastman Kodak Co.). Addi-
tional filters were immunoblotted using a 1:500 dilution of two human
IGFBP-5 antisera. The protein was detected using either an alkaline
phosphatase-conjugated goat anti-rabbit or anti-guinea pig second an-
tibodies (Sigma).
Immunoprecipitation—Cells were grown in 6-cm plates (Falcon) and
metabolically labeled with [35S]methionine for 6 h. Media were col-
lected, and the plates were rinsed twice with phosphate-buffered saline
containing 2 mg/ml bovine serum albumin (Sigma). Cells were lysed
with immunoprecipitation (IPT) buffer (25 mM Hepes, 0.1 M NaCl, 1%
Triton X-100, 10 mM EDTA) containing 1% bovine serum albumin.
35S-Labeled IGFBP-5 was immunoprecipitated from the medium by the
addition of an anti-human IGFBP-5 antibody raised in guinea pig
(1:1000 dilution) or normal guinea pig serum. The immune complexes
were precipitated by adding protein A-Sepharose (Sigma) and analyzed
by 12.5% SDS-PAGE gels, followed by autoradiography.
RNA Isolation and Northern Blot Analysis—RNA was isolated from
cell cultures using TriReagent following the manufacturer’s instruc-
tions (Molecular Research Center, Inc., Cincinnati, OH) and was quan-
tified by measuring UV absorption at A260 nm. RNA samples were size-
fractionated on a 1.2% agarose formaldehyde gel, blotted and fixed onto
a nylon membrane (ICN Biochemical, Inc., Irvine, CA), and hybridized
with the [32P]dCTP-labeled human IGFBP-5 or IGFBP-2 cDNA. A
cDNA probe for glyceraldehyde -3-phosphate dehydrogenase (GAPDH)
(Ambion, Austin, TX) was used to assess the specificity. The band
densities were quantitated by exposing the filters to phosphor screens,
which were scanned on PhosphorImagery SF followed by image anal-
ysis using ImageQuant (Molecular Dynamics).
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Clon-
ing, and DNA Sequencing—Based on the published sequences of hu-
man, rat and mouse IGFBP-5 (41, 57, 58), a set of PCR primers were
designed in the conserved regions to amplify a 393-bp region of the
coding sequence of mature IGFBP-5 (sense primer: 59-GTTTGCCT-
CAACGAAAAGAGCT-39; antisense primer: 59-CTGCTTTCTCTTGTA-
GAATCCTT-39). These primers were used in PCR with double-stranded
cDNA prepared by reverse transcription from SMC total RNA. Ampli-
fication was carried out in a DNA thermal cycler (Perkin-Elmer) using
an initial denaturation of 94 °C for 5 min, followed by 30 cycles of
denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, and
extension at 72 °C for 1 min. A 10-min incubation at 72 °C was per-
formed at the completion of the final cycle. The resulting PCR product
was cloned into a pCRy II vector from a TA cloning kit (Invitrogen). The
nucleotide sequence of the insert was sequenced following the dideoxy
nucleotide method using Sequenase version 2 (U. S. Biochemical Corp.).
Nuclear Run-on Transcription Analysis—Relative transcription
rates of IGFBP-5 and IGFBP-2 genes were measured by nuclear run-on
assay. Nuclei from control and IGF-I treated cell cultures were isolated
by a previously reported procedure (20). Isolated nuclei were stored in
liquid N2 in glycerol storage buffer (50 mM Tris, pH 8.3, 40% glycerol, 5
mMMgCl, and 0.1 mM EDTA). The run-on assay was performed at 30 °C
in 5 mM Tris-Cl (pH 8.0), 2.5 MMgCl2, 150 mM KCl, 100 mCi of [
32P]UTP,
and 1 mM each of CTP, ATP, and GTP for 30 min. Reactions were
quenched with yeast transfer RNA, treated with RNase-free DNase I
and proteinase K, and phenol-chloroform-extracted. 32P-Labeled tran-
script was purified by Quick Spiny column (Boehringer Mannheim),
treated with NaOH, and then ethanol-precipitated. Five mg of plasmid
DNA containing IGFBP-5 or IGFBP-2 insert or vector DNA were lin-
earized and NaOH-denatured, slot-blotted (BioDot, Bio-Rad), and hy-
bridized with 1 3 107 cpm 32P-labeled transcript in 10 mM TES (pH 7.4),
10 mM EDTA, 300 mM NaCl, and 0.2% SDS. Equal amounts of radio-
activity were used, and the result was quantitated on PhosphorIm-
agery SF using ImageQuant (Molecular Dynamics).
IGFBP-5 mRNA Stability—To measure the effect of IGF-I on mRNA
decay, actinomycin D or 5,6-dichloro-1-b-D-ribofuranosyl-benzimada-
zole (DRB, Sigma) dissolved in ethanol was added to cell cultures after
18 h of preincubation with or without IGF-I, and total RNA was isolated
at 1–24-h intervals. The ethanol diluent was added to control cell
cultures. After Northern blotting with IGFBP-5 cDNA probe, the abun-
dance of the mRNA was quantitated on PhosphorImagery SF (Molec-
ular Dynamics). A cDNA probe for rat 18 S rRNA was used to assess
relative amounts of RNA loaded. The t1⁄2 was defined as the time at
which the signal intensity reached 50% of that before inhibitor was
added to the cells.
Plasmid Construction and Transfection of Aortic SMC—The con-
struction of IGFBP-5 promoter/luciferase plasmid (pBP-5P/Luc) was
described previously (21). The plasmid DNA was purified by a commer-
cial Qiagen kit (Qiagen). Porcine aortic SMC cells were plated at 43 104
cells/cm2 and were maintained in culture medium as described above.
After 2 days, the cells were washed with serum-free medium and
exposed to 2 mg/well test plasmid DNA and 5 ml of Lipofectamine (Life
Technologies, Inc.) for 16 h. After transfection the cells were washed
twice and maintained in growth medium. The transfected cells were
harvested 3 days later unless otherwise specified. 0.5 mg of pSV-b-
galactosidase control vector DNA was cotransfected to determine trans-
fection efficiency. The amount of cellular extract used in the luciferase
assay was normalized relative to b-galactosidase activity. Luciferase
activities were determined using the Promega luciferase assay system.
b-Galactosidase activity was assayed by monitoring the conversion of
o-nitrophenyl-b-D-galactopyranoside to galactose and o-nitrophenyl at
A420 nm. Each experiment was repeated three to four times with dupli-
cate samples.
Statistical Analysis—Student’s t test was used to compare difference
between the control and test groups. Values are means 6 S.E. p , 0.05
was considered significant.
RESULTS
Porcine Aortic SMCs Express IGFBP-5 mRNA and Secrete
IGFBP-5 Protein—Northern blot analysis of total RNA isolated
from porcine aortic SMCs revealed a mRNA band, which hy-
bridized with a human IGFBP-5 cDNA probe under highly
stringent conditions (Fig. 1A). This transcript was the same
size (6 kb) as human IGFBP-5 mRNA found in human fibro-
blasts but was much less abundant. To make sure that this
transcript represents porcine IGFBP-5 mRNA, we performed
RT-PCR using a set of primers designed at the conserved re-
gions of mammalian IGFBP-5 and RNA isolated from porcine
SMCs as template. A DNA fragment at the predicted size (393
bp) was amplified (Fig. 1B). This PCR product was cloned into
a plasmid vector and sequenced. The predicted amino acid
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KQ (the amino acids that differ from human IGFBP-5 are
underlined). This sequence is 96% (126 out of 131 amino acids)
identical to the region between Val99 and Gln229 of human
IGFBP-5, indicating that it represents part of porcine IGFBP-5
cDNA. This porcine IGFBP-5 cDNA fragment was 32P-labeled
and hybridized to porcine SMC RNA blots. The same 6-kb
hybridizing band was observed (data not shown), indicating
that this 6-kb transcript is porcine IGFBP-5 mRNA.
To determine if porcine aortic SMCs synthesize and secrete
IGFBP-5, conditioned media (CM) from porcine SMC cultures
were subjected to Western ligand blot and immunoblot analy-
sis. As reported previously (17), ligand blotting and immuno-
blotting of CMs from confluent SMCs failed to detect IGFBP-5
(data not shown). This is likely due to the fact that porcine
SMC-CM contains abundant proteolytic activity for IGFBP-5
(22, 23). Since IGF-I and heparin have been shown to inhibit
IGFBP-5 proteolytic degradation in human fibroblasts (19, 24),
IGF-I and/or heparin were added to cell cultures prior to the
collection of medium. When heparin and IGF-I were added to
subconfluent SMC cultures, an IGFBP at the size of 31 kDa,
which comigrated with purified human IGFBP-5, was observed
by ligand blotting (Fig. 2A). The identity of this 31-kDa IGFBP
as IGFBP-5 was confirmed by immunoblotting using two dif-
ferent antibodies to human IGFBP-5 (Fig. 2B). The addition of
IGF-I increased both intact IGFBP-5 and a 22-kDa IGFBP-5
fragment, suggesting that the IGF-I-induced porcine IGFBP-5
increase may not be simply due to a decrease in degradation.
IGF-I Stimulates IGFBP-5 Synthesis—To determine if the
IGF-I-induced increase in accumulated IGFBP-5 is due to an
increase in synthesis or decrease in degradation or both, im-
munoprecipitation of [35S]methionine-labeled newly synthe-
sized IGFBP-5 was performed. As shown in Fig. 3, most newly
synthesized IGFBP-5 was degraded in porcine SMCs under
basal conditions. Therefore, only a 22-kDa IGFBP-5 fragment
was detectable in media from control cultures (Fig. 3A, lane 2).
The addition of heparin decreased the intensity of the IGFBP-5
fragment (50% of the control) and induced the appearance of
the intact IGFBP-5 doublet band (Fig. 3A, lane 3). The addition
of IGF-I alone caused a moderate increase in intact IGFBP-5
and a greater increase in the intensity of the IGFBP-5 frag-
ment (435% above control; Fig. 3A, lane 4, and Fig. 3B). The
addition of IGF-I together with heparin resulted in a 220%
increase in the levels of intact IGFBP-5 compared with heparin
alone and a 180% increase in the fragment (Fig. 3, panel A, lane
5, and panel B). When immunoprecipitation was performed
using normal guinea pig serum, neither intact nor fragment
IGFBP-5 was detected (Fig. 3A, lane 1). These data indicate
that IGF-I increases the IGFBP-5 levels in porcine SMC-CM
primarily by stimulating IGFBP-5 synthesis.
IGF-I Increases the Steady-state Levels of IGFBP-5
mRNA—To examine if IGF-I-induced increase in IGFBP-5 syn-
thesis was regulated at the level of mRNA abundance, total
RNA was isolated from SMCs treated with or without IGF-I
FIG. 1. Porcine aortic SMCs express IGFBP-5 mRNA. A, North-
ern blot analyses of IGFBP-5 mRNA levels. Ten mg of total RNA isolated
from A673 human rhabdomyosarcoma cells (lane 1), GM-10 human
fibroblasts (lane 2), and porcine aortic SMCs (lane 3) was loaded and
subjected to Northern blotting using a human IGFBP-5 cDNA probe
and a GAPDH cDNA probe. The arrows denote the 6-kb IGFBP-5
message and 1.4-kb GAPDH message. B, RT-PCR amplification of por-
cine IGFBP-5 mRNA. One mg of total RNA isolated from GM-10 human
fibroblasts (lane 2) or porcine aortic SMCs (lane 3) was reverse tran-
scribed into cDNA followed by PCR amplification, as described under
“Experimental Procedures.” Lane 1 is the 1-kb DNA ladder.
FIG. 2. Porcine aortic SMCs secrete IGFBP-5. A, ligand blot
analysis of porcine SMC conditioned media. The 24-h conditioned me-
dium (0.5 ml) from control (lane 2) or IGF-I (100 ng/ml)-treated SMC
cultures (lane 3) was concentrated 20 times and separated by 12.5%
SDS-PAGE gel. Heparin (100 mg/ml) was added 6 h prior to the collec-
tion. Lane 1 contains human IGFBP-5 (100 ng). B, immunoblot analysis
of porcine SMC conditioned media. The same 24-h conditioned medium
samples shown in panel A from control (lanes 2 and 4) or IGF-I (100
ng/ml)-treated SMCs (lanes 3 and 5) were immunoblotted with a human
IGFBP-5 antibody prepared in rabbit (lanes 2 and 3) or in guinea pig
(lanes 4 and 5). Lane 1 contains purified human IGFBP-5 (100 ng).
FIG. 3. IGF-I stimulates IGFBP-5 synthesis in porcine aortic
SMCs. A, autoradiogram showing the effect of IGF-I and/or heparin on
newly synthesized IGFBP-5. Porcine SMCs were preincubated without
(lanes 1–3) or with IGF-I (100 ng/ml, lanes 4 and 5) for 18 h followed by
a 1-h incubation in methionine-free medium before the addition of 50
mCi of [35S]methionine without (lanes 1, 2, and 4) or with heparin (100
mg/ml, lanes 3 and 5). After 6 h, culture media were collected and
immunoprecipitated using normal guinea pig serum (lane 1) or human
IGFBP-5 antiserum prepared in guinea pig (lanes 2–5). The pellets were
boiled in sample buffer for 10 min and analyzed by SDS-PAGE followed
by autoradiography. B, phosphorimager analysis. Values are means of
two immunoprecipitation experiments as described in A.
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and subjected to Northern blot analysis. IGF-I treatment
caused significant increases in the steady-state levels of IG-
FBP-5 mRNA in a dose-dependent manner (Fig. 4, A and C).
When incubated for 24 h, IGF-I treatment significantly in-
creased IGFBP-5 mRNA levels using concentrations from 50 to
250 ng/ml (p , 0.05). IGF-I (250 ng/ml) caused a 448% increase,
while 228% and 57% increases were observed using concentra-
tions of 50 and 5 ng/ml, respectively. In contrast to IGFBP-5,
IGF-I treatment had no effect in on IGFBP-2 mRNA levels.
IGF-I at the highest concentration (250 ng/ml) appeared to
slightly increase GAPDH mRNA levels (63%, Fig. 4, A and C).
This increase, however, was much less than the increase in
IGFBP-5 mRNA and could reflect an increase in total protein
synthesis that occurs with IGF-I treatment of SMCs (18). IGF-I
induced IGFBP-5 mRNA levels in a time-related fashion (Fig.
4, B and D). IGF-I (100 ng/ml) caused significant 147% and
217% increases in IGFBP-5 mRNA levels after 6 and 12 h of
incubation, respectively. A greater response (497% of the con-
trol values) was seen after 24 h. The induction of IGFBP-5
mRNA levels appeared to be specific for IGF-I. Addition of
FGF, either alone or in combination with IGF-I, did not further
increase IGFBP-5 mRNA levels (Fig. 5, A and B). PDGF, on the
other hand, caused a moderate decrease in the presence (40%)
or absence of IGF-I (21%). These results indicated that the
stimulation of IGFBP-5 synthesis by IGF-I is regulated at the
level of mRNA abundance in porcine SMCs and that this effect
is IGF-I-specific.
The IGF-I-induced IGFBP-5 mRNA Expression Is Mediated
through the IGF-I Receptors—The effect of IGF-I was compared
with two IGF-I-related peptides, IGF-II and insulin, which bind
to the IGF-I receptors with lower affinity. As shown in Fig. 6
(A and C), IGF-II and insulin were effective at high concentra-
tions, but less potent. IGF-II at the concentration of 50 ng/ml
caused a 110% increase in comparison to a 243% increase by
IGF-I at the same concentration. Insulin had little effect at this
dose. A very high dose of insulin (1 mg/ml) evoked a moderate
FIG. 5. A, autoradiogram showing the effects of PDGF and FGF on
IGF-I-induced IGFBP-5 mRNA expression. Porcine aortic SMCs were
incubated in serum-free medium without (lane 1) or with IGF-I (100
ng/ml, lane 2), PDGF (5 ng/ml, lane 3), FGF (50 ng/ml, lane 4), IGF-I
plus PDGF (lane 5), or IGF-I plus FGF (lane 6) for 24 h. Total RNA was
isolated from SMC cultures and subjected to Northern blotting with
cDNA probes for IGFBP-5 and GAPDH. B, phosphorimager analysis of
three experiments as described in A. Values are means 6 S.E. ex-
pressed as a percentage of mRNA levels in the control, untreated
samples. *, significantly different from the controls (p , 0.05).
FIG. 4. IGF-I increases the steady-
state levels of IGFBP-5 mRNA in por-
cine aortic SMCs. A, autoradiogram
showing dose-dependent effect of IGF-I.
Porcine SMC cultures were treated with-
out (lane 1) or with 1 (lane 2), 5 (lane 3),
50 (lane 4), and 250 ng/ml IGF-I (lane 5)
for 24 h. Total RNA was isolated from
SMC cultures and subjected to Northern
blot with cDNA probes for IGFBP-5, IG-
FBP-2, and GAPDH. B, autoradiogram
showing the time-course effect of IGF-I.
Porcine SMC cultures were preincubated
in serum-free medium for 24 h and then
treated without (lanes 1, 2, 4, 6, 8, and 10)
or with 100 ng/ml IGF-I (lanes 3, 5, 7, 9,
and 11) for 0 (lane 1), 1 (lanes 2 and 3), 3
(lanes 4 and 5), 6 (lanes 6 and 7), 12 (lanes
8 and 9), and 24 h (lanes 10 and 11). C and
D, phosphorimager analyses of the con-
centration dependence and time-course
experiments, respectively. Values are
means 6 S.E. of four (C) or three (D)
separate experiments. They are ex-
pressed as a percentage of mRNA levels
in the control, untreated samples. *, sig-
nificantly different from the controls (p ,
0.05).
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increase (140%). These data suggested that the IGF-I receptor
mediated this effect. We attempted to determine if this effect of
IGF-I was mediated by the IGF-I receptor by selectively block-
ing the receptor using the monoclonal blocking antibody, aIR3.
Surprisingly, the antibody did not inhibit the IGF-I-induced
increase (Fig. 6C, lane 4) and caused a 436% increase in IG-
FBP-5 mRNA levels in porcine SMCs (Fig. 6C, lane 3). This is
unlikely to be due to the use of this anti-human IGF-I receptor
antibody in a heterologous system, since aIR3 induced a simi-
lar increase of IGFBP-5 mRNA expression in human aortic
SMCs (data not shown). Thus, the induction of IGFBP-5 by
IGF-I could not be assessed under conditions of selective recep-
tor blockage. We next examined the effects of IGF analogs,
Des(1–3)-IGF-I and [Leu24]IGF-I(1–60). Des(1–3)-IGF-I is an
IGF-I analog with normal affinity for IGF-I receptors but with
remarkably reduced affinity for IGFBPs. This peptide evoked a
similar 705% increase in IGFBP-5 mRNA levels in porcine
SMCs (Fig. 6, panel C, lane 5, and panel D). On the other hand,
[Leu24]IGF-I(1–60), which binds to IGFBPs normally but does
not bind to the IGF receptors, had no effect (Fig. 6, panel C,
lane 6, and panel D). Therefore, the stimulation of IGFBP-5
expression by IGF-I appears to be mediated through the IGF-I
receptor.
IGF-I Induces IGFBP-5 Expression through Transcriptional
Activation of the IGFBP-5 Gene—The elevation in IGFBP-5
mRNA levels and protein synthesis observed after IGF-I treat-
ment could reflect transcriptional activation of the gene and/or
posttranscriptional events. To determine if IGF-I induces IG-
FBP-5 mRNA levels by transcriptional mechanisms, nuclear
run-on assays were performed on nuclei isolated from control
and SMCs that had been treated with IGF-I. As shown in Fig. 7,
IGF-I treatment increased the level of IGFBP-5 transcription
rate an average of 289% above base line in two separate exper-
iments, whereas no difference was seen with IGFBP-2 tran-
scripts, suggesting that the increase in the steady-state levels
of IGFBP-5 mRNA induced by IGF-I is due at least in part to an
increase in the rate of transcription.
We also sought to determine if IGF-I treatment affects IG-
FBP-5 mRNA stability. Porcine aortic SMCs were incubated
with or without IGF-I for 18 h, and then treated with actino-
mycin D. Although there was no difference in the calculated t1⁄2
of IGFBP-5 mRNA in the control and IGF-I-treated groups,
treatment of actinomycin D caused a transient rise in IGFBP-5
mRNA levels (data not shown). This actinomycin D-associated
increase in IGFBP-5 mRNA levels has previously been ob-
served in human breast carcinoma cells (25) and complicated
the interpretation of these data. We next performed similar
experiments using the RNA polymerase II inhibitor DRB. Ad-
dition of DRB to porcine SMCs led to a progressive decline in
IGFBP-5 abundance (Fig. 8A) with a calculated t1⁄2 for both
control and IGF-I-treated groups of approximately 18 h (Fig.
8B). Thus, IGF-I treatment does not cause an alternation in
IGFBP-5 mRNA stability.
These results indicate that the increase in the levels of
IGFBP-5 mRNA induced by IGF-I is primarily due to the acti-
vation of the IGFBP-5 gene. We wondered whether IGF-I mod-
ulates IGFBP-5 transcripts by direct interaction with the 59- or
FIG. 7. IGF-I stimulates the transcription rate of the IGFBP-5
gene in porcine aortic SMCs. A, autoradiogram showing the effect of
IGF-I. Nuclei from control and IGF-I-treated cultures were isolated and
nuclear run-on assays performed in the presence of [32P]UTP for 30
min. The nascent 32P-labeled transcripts were hybridized to slots of
filter-bound IGFBP-2 (lane 1), IGFBP-5 (lane 2), and pBluescript DNA
(lane 3). B, phosphorImager analysis of two separate experiments.
Values are means expressed as a percentage of mRNA levels in the
control, untreated samples.
FIG. 6. The effect of IGF-I on IG-
FBP-5 gene expression is mediated
through the IGF-I receptor. A, autora-
diogram showing the effects of IGF-I,
IGF-II, and insulin. Porcine aortic SMCs
were incubated with serum-free medium
(lane 1), or serum-free medium plus IGF-I
(10 ng/ml, lane 2; 50 ng/ml, lane 3), IGF-II
(50 ng/ml, lane 4), or insulin (1 mg/ml,
lane 5) for 24 h. B, autoradiogram show-
ing the effects of IGF analogs and the
IGF-I receptor blocking antibody aIR3.
Porcine SMCs were incubated with se-
rum-free medium (lane 1), or serum-free
medium with IGF-I (100 ng/ml, lane 2),
aIR3 (10 mg/ml, lane 3), IGF-I (100 ng/ml)
plus aIR3 (10 mg/ml, lane 4), Des(1–3)-
IGF-I (100 ng/ml, lane 5), or [Leu24]IGF-
I(1–60) (100 ng/ml, lane 6) for 24 h. C and
D, phosphorimager analyses of three ex-
periments as described in A and B, re-
spectively. Values are means 6 S.E. ex-
pressed as a percentage of mRNA levels
in the control, untreated samples. *, sig-
nificantly different from the controls (p ,
0.05).
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39-regulatory sequences or, alternatively, by inducing the syn-
thesis of an intermediate regulatory factor(s). Accordingly, por-
cine SMCs were treated with IGF-I in the presence and absence
of cycloheximide. As shown in Fig. 9, while IGF-I alone induced
a 656% increase, co-incubation with cycloheximide completely
blocked the IGF-I-induced IGFBP-5 gene expression (151% of
the controls), suggesting this effect of IGF-I requires de novo
protein synthesis.
In order to gain insight into the promoter region(s) of the
IGFBP-5 gene responsive to IGF-I, we transfected SMCs with a
1278-bp segment of human IGFBP-5 promoter fused to the
reporter luciferase gene. This segment of the IGFBP-5 pro-
moter contains identical sequences of a number of well defined
regulatory elements, including a TATA box, a CAAT box, and
several AP-2 elements, which previously have been shown to be
responsible for the cAMP-induced activation of this gene (21).
As shown in Fig. 10A, relative luciferase activity in IGF-I-
treated SMCs was 345% higher than those of the control SMCs
(p , 0.05). This indicates that this 1278-base pair promoter
region contains a cis-acting element(s) that is responsible for
the IGFBP-5 gene response to IGF-I.
The Regulation of IGFBP-5 Gene Expression by IGF-I Is Cell
Type-specific—Since previous studies showed that IGF-I treat-
ment does not result in a significant change in IGFBP-5 mRNA
levels in human fibroblasts, human osteosarcoma, and breast
carcinoma cells (19, 26, 27, 37, 38), we wondered if the stimu-
lation of IGFBP-5 gene expression by IGF-I seen in porcine
SMCs reflects a cell type-specific regulation or is simply due to
different species used. To determine this, we examined the
effect of IGF-I on IGFBP-5 expression in a number of human
cell lines derived from different tissues. Similar to porcine
aortic SMC, IGF-I treatment (100 ng/ml, 24 h) resulted in a
significant increase (320 6 53%) in the steady-state levels of
IGFBP-5 mRNA in human newborn aortic SMCs (Fig. 11A). In
contrast to aortic SMCs, human fetal skin fibroblasts (GM-10),
glioblastoma cell (T98G), and human intestinal SMCs had
abundant IGFBP-5 mRNA levels under basal conditions (Fig. 11,
B–D). IGF-I treatment did not change the IGFBP-5 mRNA
levels in these cells. In addition, in human fibroblasts trans-
fected with the IGFBP-5 promoter/luciferase chimerical con-
structs, relative luciferase activity did not change when IGF-I
was added (Fig. 10B). These results indicate that the up-regu-
FIG. 8. IGF-I does not cause alteration in the stability of IG-
FBP-5 mRNA in porcine aortic SMCs. A, autoradiogram showing a
representative Northern blot. Porcine aortic SMCs were incubated
without (lanes 1–9) or with IGF-I (lanes 10–18) for 18 h, followed by the
addition of vehicle (lanes 2–5 and 11–14) or DRB at 75 mM concentration
(lanes 6–9 and 15–18). The cells were harvested at 0 (lanes 1 and 10), 3
(lanes 2, 6, 11, and 15), 6 (lanes 3, 7, 12, and 16), 12 (lanes 4, 8, 13, and
17), and 24 h (lanes 5, 9, 14, and 18) after the addition of DRB or vehicle.
Total RNA was isolated and subjected to Northern blotting with cDNA
probes for IGFBP-5 and 18 S rRNA. B, effect of IGF-I on IGFBP-5
mRNA decay in transcriptionally blocked porcine SMCs. Values are
means of two separate experiments expressed as a percentage of levels
in the control, untreated samples.
FIG. 9. The protein synthesis inhibitor cycloheximide abro-
gates the IGF-I-induced IGFBP-5 expression. A, autoradiogram
showing the inhibitory effect of cycloheximide. Porcine aortic SMC
cultures were incubated without (lanes 1 and 3) or with IGF-I (100
ng/ml, lanes 2 and 4) in the presence (lanes 1 and 2) or absence (lanes
3 and 4) of cycloheximide (10 mg/ml) for 24 h. Total RNA was isolated
from SMC cultures and subjected to Northern blotting with cDNA
probes for IGFBP-5 and GAPDH. B, phosphorimager analysis. Values
are means of two separate experiments expressed as a percentage of
levels in the control, untreated samples.
FIG. 10. Effect of IGF-I on human IGFBP-5 promoter activity
in aortic SMCs (A) and fibroblasts (B). A 1278-bp DNA fragment of
the human IGFBP-5 gene 59-flanking region was fused to a luciferase
reporter gene (pGL2-Basic) and transiently transfected into porcine
SMCs and GM-10 fibroblasts. After growing in complete medium for 72
h, cells were incubated in serum-free medium with or without IGF-I
(100 ng) for another 6 h. The cellular extracts were prepared and the
luciferase activity was measured as described under “Experimental
Procedures.” The relative luciferase activities represent the relative
value normalized by galactosidase activity. Values are means 6 S.E.
expressed as a percentage of the levels in the controls. * Significantly
different from the controls (p , 0.05).
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lation of IGFBP-5 gene expression by IGF-I occurs in human
and porcine aortic SMCs and this regulation is cell
type-specific.
DISCUSSION
The present study demonstrates that porcine as well as
human aortic SMCs express IGFBP-5 mRNA and secrete the
protein. In this cell type, the biosynthesis of IGFBP-5 is stim-
ulated by IGF-I. IGF-I regulates IGFBP-5 synthesis at the
mRNA level. This effect of IGF-I appears to be mediated by the
IGF-I receptor and requires de novo protein synthesis. The
increase in IGFBP-5 mRNA levels that is induced by IGF-I is
primarily due to an elevation in the transcription rate of the
IGFBP-5 gene rather than an alteration in the stability of the
transcript, suggesting that IGF-I regulates IGFBP-5 expres-
sion primarily by transcriptional activation of the gene in aortic
SMCs.
The expression of the IGFBP-5 gene is cell type-specific.
High levels of IGFBP-5 mRNA have been found in fibroblasts,
glioblastoma cells, skeletal muscle cells, osteoblasts, chondro-
cytes, granulosa cells, and thyroid cells but not in hepatoma or
rhabdomyosarcoma cells (19, 21, 26, 28–30, 55, 56). Although
the aortic SMC has been extensively used as a model to study
the IGF system, there was no previous report regarding the
expression of IGFBP-5 in this cell type. Several experimental
difficulties seem to be partly responsible. First, aortic SMC-CM
contains abundant proteolytic activity for IGFBP-5. SMC-CM
has been shown to rapidly degrade exogenously added human
IGFBP-5 (22, 23). As shown in this study, the endogenously
secreted IGFBP-5 was completely degraded yielding small frag-
ments under basal conditions unless IGF-I and/or heparin was
added to the culture medium (Figs. 2 and 3). Second, endog-
enously produced IGFBP-5 (31 kDa) was difficult to distinguish
from 32-kDa IGFBP-2, which is the predominant form of IG-
FBP secreted by porcine SMCs that is detected by Western
ligand blotting. Third, the IGFBP-5 production by SMCs is
inversely correlated to cell density. IGFBP-5 mRNA levels were
4–5-fold lower in postconfluent cultures as compared with sub-
confluent SMC cultures.2 In this study, we used subconfluent
cultures, whereas in previous studies confluent cultures were
used (17, 31).
The fact that aortic SMCs synthesize IGFBP-5 and that its
synthesis is under the regulation of IGF-I implies that this
binding protein may play an important role in modulating
IGF-induced SMC proliferation and migration. IGFBP-5 has
been shown to have the unique property of adhering to extra-
cellular matrix (32). When associated with the extracellular
matrix, it has been shown to potentiate the effect of IGFs on
fibroblast growth. In addition, IGFBP-5 may also be involved in
muscle cell differentiation. The expression of IGFBP-5 is
greatly increased during terminal differentiation of the mouse
myoblast cell lines (33–35). This process is also stimulated by
IGFs. The exact physiological function(s) of IGFBP-5 in aortic
SMC proliferation and migration is currently under
investigation.
The abundance of IGFBP-5 is influenced by a number of
factors. Of the substances studied, IGF-I was the most potent
regulator in aortic SMCs. IGF-I increased the IGFBP-5 protein
as well as IGFBP-5 mRNA levels. The effect of IGF-I in induc-
ing IGFBP-5 expression is specific. IGF-I had no effect on
IGFBP-2 mRNA level. There was a small increase in GAPDH
mRNA, but this change was negligible in comparison to a
severalfold increase in IGFBP-5. Two other SMC mitogenic
factors, FGF and PDGF, had no stimulatory effect. In fact,
PDGF acts as a inhibitor of IGFBP-5 expression either added
alone or in combination with IGF-I. This inhibitory effect of
PDGF was previously observed in rat osteoblasts (36). An in-
crease in IGFBP-5 abundance in CM induced by IGF-I was
previously reported in human fibroblasts and other cells (19,
26–29, 37, 55, 56). However, inconsistent and confusing results
have been documented regarding the mechanisms accounting
for this increase. In human fibroblasts, U2 osteosarcoma cells
and breast carcinoma cells, IGF-I treatment significantly in-
creases the IGFBP-5 protein concentrations without affecting
the IGFBP-5 mRNA abundance (19, 26, 27, 37, 38). This effect
of IGF-I may be attributed to the inhibition of IGFBP-5 prote-
olysis rather than an alteration of the biosynthesis in these
cells. In rat FRTL-5 thyroid cells and osteoblasts, on the other
hand, IGF-I stimulated IGFBP-5 concentrations with a con-
comitant increase in IGFBP-5 mRNA levels, suggesting that
IGF-I may regulate the IGFBP-5 abundance by simulating its
synthesis (28, 29).
In this study, we have directly demonstrated that IGF-I
induces an increase in IGFBP-5 synthesis in aortic SMCs by
using metabolic labeling of porcine SMCs coupled with immu-
noprecipitation. Although porcine SMC conditioned medium
contains IGFBP-5 protease activity, IGF-I does not appear to
greatly affect proteolysis. IGF-I treatment resulted in an in-
crease in the newly synthesized intact IGFBP-5 as well as the
proteolytically degraded fragment, while heparin only in-
creased the intact protein levels by inhibiting the degradation
(Fig. 3). Therefore IGF-I regulates the IGFBP-5 abundance in
porcine SMCs primarily by increasing the biosynthesis. These
results are consistent with the previous data obtained in rat
thyroid cells and osteoblasts, but different from those of human
fibroblasts, human osteosarcoma, and breast carcinoma cells.
Since the cell models used in the above studies are derived from
different tissues and species, this discrepancy may reflect cell-
specific regulation or species differences. A recent study using
human and bovine fibroblasts suggested a possible species
difference may exist (27). We addressed this question by exam-
ining IGF-I-induced IGFBP-5 gene expression in a number of
human cell types. Our data with human aortic SMCs, human
skin fibroblasts, human glioblastoma cells, and intestinal
SMCs (Fig. 11) indicate that the stimulation of IGFBP-5 gene
transcription by IGF-I is a cell type-specific event. This conclu-
sion is in agreement with the fact that the structure of the
IGFBP-5 promoter is highly conserved among mammalian spe-
cies. The proximal 200 bp of the IGFBP-5 gene promoter, which
has been shown to contain the primary promoter activity (39),
is more than 90% identical among human, mouse, and rat
(40–42). Therefore, it is unlikely species difference is the sole
factor accounting for the different regulation of IGFBP-52 C. Duan and D. R. Clemmons, unpublished observation.
FIG. 11. IGF-I stimulates IGFBP-5 gene expression in human
aortic SMCs (A) but not in human fibroblasts (B), glioblastoma
(C), and human intestinal SMCs (D). Confluent cells were incubated
without (lane 1) or with IGF-I (100 ng/ml, lane 2) for 24 h. Total RNA
was isolated, and 15-mg RNA aliquots were loaded and subjected to
Northern blotting with cDNA probes for IGFBP-5 and GAPDH.
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synthesis.
Although previous studies have demonstrated IGF-I-induced
IGFBP-5 mRNA steady-state levels in other cell types (27–29),
the pathways and mechanisms responsible for the rise in IG-
FBP-5 mRNA levels have not been established. In this study,
we attempted to delineate whether IGF-I operates through the
IGF-I receptor to induce IGFBP-5 gene expression. Because the
anti-IGF-I receptor antibody (aIR3) behaved as a partial ago-
nist in stimulating IGFBP-5 expression, definite proof that
type I IGF-I receptor stimulation accounts for IGFBP-5 induc-
tion could not be obtained. The partial agonist activity seen
here with aIR3 has been reported previously with IGF-I-in-
duced c-myc induction in human SMCs (43). Our experiments
using IGF-II, insulin, and IGF analogs, however, strongly sug-
gest that the stimulation of IGFBP-5 expression by IGF-I is
mediated through the IGF-I receptor.
The data presented in this study demonstrate that IGF-I
treatment transcriptionally activates the IGFBP-5 gene with-
out altering the transcript stability. The IGFBP-5 gene expres-
sion is activated within 6 h of exposure to IGF-I, as indicated by
Northern blotting and transient gene transfer studies. Coupled
with the relatively long half-life of IGFBP-5 mRNA in porcine
aortic SMCs (18 h), the progressive acceleration of the tran-
scription rate is sufficient to result in a substantial increase in
mRNA expression, protein synthesis, and secretion into the
culture medium. The transcriptional activation of the IGFBP-5
gene by IGF-I in aortic SMCs was further ascertained by the
results of gene transfer studies in SMCs. A fusion plasmid
containing 1278 bp of 59-flanking region of human IGFBP-5
gene showed an IGF-I-induced rise in directing reporter gene
expression (Fig. 10). These observations indicate that IGF-I is
able to activate the IGFBP-5 gene through cis-acting ele-
ment(s) residing on this 1278-bp region. IGF-I has been shown
to regulate transcription of a number of genes, e.g. c-myc (43),
growth hormone (44), thyroglobulin (45), d1-crystallin (46),
elastin (47), P-450 cholesterol side chain cleavage gene (48),
and others (49). However, little is known regarding the cis-
DNA sequences responsive to IGF-I. Recently, IGF-I was
shown to regulate chicken d1-crystallin gene expression
through a GC-rich sequence that binds to a Sp-1-like protein
(46). In the rat elastin promoter, a similar but not identical
GC-rich sequence is capable of binding to IGF-I-regulated pro-
teins and responsible for the IGF-I-responsiveness of this gene
(47). One of the proteins has been shown to be Sp-1 (50). The
IGFBP-5 promoter contains several GC-rich regions superfi-
cially resembling the Sp-1 element. In particular, the DNA
sequence 59-CCCCACCCCCACCC-39 at position 2147 to 2134
has this potential. Although this highly conserved sequence
contains two overlapping AP-2 elements (59-CCCCACCC-39)
and is capable of binding to AP-2 in vitro, it does not appear to
mediate the AP-2 regulation under basal condition in vivo (21).
This sequence contains sequences identical to the retinoblas-
toma (Rb) control element 59-CCACCC-39. The Rb control ele-
ment motif has been identified as a Sp-1-binding sequence
responsible for Rb-induced trans-activation (51). A recent study
by Jensen et al. (50) suggested that IGF-I may disrupt Sp-1
binding to the GC-rich domain of the elastin gene by affecting
the phosphorylation state of Rb in rat SMCs. Studies using
transient transfection assays are currently under way to deter-
mine if this sequence and/or other sequence(s) is required for
IGFBP-5 gene to be activated in response to IGF-I.
Our results have shown that IGF-I up-regulates IGFBP-5
gene expression in a dose-dependent fashion and in a time
frame consistent with that of an intermediate effect. The find-
ing that cycloheximide abrogates IGF-I-induced IGFBP-5 tran-
scription suggests a requirement for the synthesis of an inter-
mediate protein(s). It has been reported that IGF-I stimulates
the expression the immediate-early gene c-fos in several cell
types (52, 59). The encoded proteins Fos can dimerize with Jun
and form the AP-1 complex, a transcriptional activator that
regulates many genes (53). An elevation in AP-1 transcrip-
tional activity induced by IGF-I has recently been observed in
IEC-6 intestinal epithelial cells (60). Although a consensus
AP-1 element is present in the rat IGFBP-5 promoter region
(2314 to 2320 bp; Ref. 42), there is no evidence that this AP-1
element is functional in rat. Moreover, this sequence is not
conserved even among mammalian species; a single residue
alteration from T to C leads to the ablation of the potential
AP-1 element in the human IGFBP-5 promoter (40). One of the
other genes that responds rapidly to IGF-I is the prereplicative
(G1) phase-specific cyclin D1. This gene is activated by IGF-I
treatment within 1 h in MG63 human osteosarcoma cells (54).
D-type cyclins are known to be able to form complexes with Rb
and affect Rb phosphorylation status (61, 62). The phosphoryl-
ation states of Rb are reported to be affected by IGF-I in aortic
SMCs, and this change appears to be related to the IGF-I-
induced disruption of Sp-1 binding of the rat elastin gene (50).
Further studies are needed to determine which mechanism(s)
IGF-I uses to activate IGFBP-5 gene transcription in aortic
SMCs.
In summary, aortic SMCs synthesize IGFBP-5 in addition to
previously identified IGFBP-2 and -4. The abundance of this
important modulator of IGF activity is regulated by its own
ligand, IGF-I. IGF-I regulates IGFBP-5 synthesis by activating
transcription of the IGFBP-5 gene rather than altering the
stability of the transcript. This effect of IGF-I appears to be
mediated by the IGF-I receptor and is aortic SMC-specific.
Since IGF-I is important for aortic SMC proliferation and mi-
gration, analysis of the regulation of IGFBP-5 gene expression
and action in SMCs should provide insight into the role of the
IGF system in the development of atherosclerotic lesions.
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